U.S. Jury Orders Actos Manufacturers To Pay $9 Billion In Damages

Following the conclusion of a trial that began on February 3 in the U.S. District Court for the Western District of Louisiana, a U.S. jury ordered Takeda and Eli Lilly to pay a combined $9 billion in punitive damages after finding that the companies concealed the cancer risks associated with the diabetes therapy, Actos (pioglitazone). The jury in Allen v. Takeda Pharmaceuticals North America Inc., 12-cv-00064 also awarded compensatory damages to the plaintiff of nearly $1.5 million.

This was the first Actos MDL trial to go forward.  More than 2,700 other similar Actos suits remain consolidated before U.S. District Judge Rebecca Doherty in Louisiana in MDL 2299.  The Allen case was selected as a “bellwether” case.  Bellwether trials are often utilized in mass tort pharmaceutical and medical device litigations when large numbers of plaintiffs are proceeding on the same theory or claim.  These representative cases go to trial and the results may be analyzed in valuing groups of claims in potential settlements.

What Should I Do If I Got Bladder Cancer From Taking Actos?

Our experienced medical drug and device attorneys are actively involved in the Actos MDL litigation. You can call the firm toll free at (888)841-9623 or online by submitting the free case evaluation form found on this page.

Zoll, Kranz & Borgess, LLC – Actos attorneys